MedKoo Cat#: 575718 | Name: Furegrelate sodium hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Furegrelate sodium is a thromboxane synthase inhibitor that attenuates the renal vasoconstriction of angiotensin II, presumably by enhancing the formation of vasodilator prostaglandins.

Chemical Structure

Furegrelate sodium hydrate
Furegrelate sodium hydrate
CAS#87463-91-0 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 575718

Name: Furegrelate sodium hydrate

CAS#: 87463-91-0 (sodium hydrate)

Chemical Formula: C15H12NNaO4

Exact Mass: 0.0000

Molecular Weight: 293.25

Elemental Analysis: C, 61.44; H, 4.12; N, 4.78; Na, 7.84; O, 21.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Furegrelate sodium hydrate; U 63557A; U-63557A; U63557A
IUPAC/Chemical Name
Sodium 5-(3-pyridylmethyl)-2-benzofurancarboxylate monohydrate
InChi Key
UVXKTLQOOXTOML-UHFFFAOYSA-M
InChi Code
InChI=1S/C15H11NO3.Na.H2O/c17-15(18)14-8-12-7-10(3-4-13(12)19-14)6-11-2-1-5-16-9-11;;/h1-5,7-9H,6H2,(H,17,18);;1H2/q;+1;/p-1
SMILES Code
O=C(C1=CC2=CC(CC3=CC=CN=C3)=CC=C2O1)[O-].[H]O[H].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 293.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hirenallur-S DK, Detweiler ND, Haworth ST, Leming JT, Gordon JB, Rusch NJ. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. doi: 10.4103/2045-8932.97605. PubMed PMID: 22837860; PubMed Central PMCID: PMC3401873. 2: Pestel S, Nath A, Jungermann K, Schieferdecker HL. Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate. Biochem Pharmacol. 2003 Aug 15;66(4):643-52. PubMed PMID: 12906929. 3: Kaushal RD, Wilson TW. Effect of furegrelate on renal plasma flow after angiotensin II infusion. Can J Physiol Pharmacol. 1990 Apr;68(4):500-4. PubMed PMID: 2328452. 4: Martorell A, Sagredo A, Aras-López R, Balfagón G, Ferrer M. Ovariectomy increases the formation of prostanoids and modulates their role in acetylcholine-induced relaxation and nitric oxide release in the rat aorta. Cardiovasc Res. 2009 Nov 1;84(2):300-8. doi: 10.1093/cvr/cvp214. Epub 2009 Jun 30. PubMed PMID: 19567483.